Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization.

ICD codes Marijuana Tetrahydrocannabinol cannabis decriminalization legalization recreational use urine drug screen

Journal

Clinical toxicology (Philadelphia, Pa.)
ISSN: 1556-9519
Titre abrégé: Clin Toxicol (Phila)
Pays: England
ID NLM: 101241654

Informations de publication

Date de publication:
04 2023
Historique:
medline: 3 5 2023
pubmed: 2 5 2023
entrez: 2 5 2023
Statut: ppublish

Résumé

Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-related emergency department visits in states with varying degrees of legalization. Seventeen healthcare institutions in fifteen states (California, Colorado, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Missouri, New Hampshire, Oregon, South Carolina, Tennessee, Texas, Washington) participated. Cannabinoid immunoassay results and cannabis-related International Classification of Diseases (ninth and tenth versions) codes were obtained for emergency department visits over a 3- to 8-year period during various stages of legalization: no state laws, decriminalized, medical approval before dispensaries, medical dispensaries available, recreational approval before dispensaries and recreational dispensaries available. Trends and monthly rates of cannabinoid immunoassay and cannabis-related International Classification of Diseases code positivity were determined during these legalization periods. For most states, there was a significant increase in both cannabinoid immunoassay and International Classification of Diseases code positivity as legalization progressed; however, positivity rates differed. The availability of dispensaries may impact positivity in states with medical and/or recreational approval. In most states with no laws, there was a significant but smaller increase in cannabinoid immunoassay positivity rates. States may experience an increase in cannabis-related emergency department visits with progression toward marijuana legalization. The differences between states, including those in which no impact was seen, are likely multifactorial and include cultural norms, attitudes of local law enforcement, differing patient populations, legalization in surrounding states, availability of dispensaries, various ordering protocols in the emergency department, and the prevalence of non-regulated cannabis products.

Sections du résumé

BACKGROUND
Many states in the United States have progressed towards legalization of marijuana including decriminalization, medicinal and/or recreational use. We studied the impact of legalization on cannabis-related emergency department visits in states with varying degrees of legalization.
METHODS
Seventeen healthcare institutions in fifteen states (California, Colorado, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Missouri, New Hampshire, Oregon, South Carolina, Tennessee, Texas, Washington) participated. Cannabinoid immunoassay results and cannabis-related International Classification of Diseases (ninth and tenth versions) codes were obtained for emergency department visits over a 3- to 8-year period during various stages of legalization: no state laws, decriminalized, medical approval before dispensaries, medical dispensaries available, recreational approval before dispensaries and recreational dispensaries available. Trends and monthly rates of cannabinoid immunoassay and cannabis-related International Classification of Diseases code positivity were determined during these legalization periods.
RESULTS
For most states, there was a significant increase in both cannabinoid immunoassay and International Classification of Diseases code positivity as legalization progressed; however, positivity rates differed. The availability of dispensaries may impact positivity in states with medical and/or recreational approval. In most states with no laws, there was a significant but smaller increase in cannabinoid immunoassay positivity rates.
CONCLUSIONS
States may experience an increase in cannabis-related emergency department visits with progression toward marijuana legalization. The differences between states, including those in which no impact was seen, are likely multifactorial and include cultural norms, attitudes of local law enforcement, differing patient populations, legalization in surrounding states, availability of dispensaries, various ordering protocols in the emergency department, and the prevalence of non-regulated cannabis products.

Identifiants

pubmed: 37129223
doi: 10.1080/15563650.2023.2177552
doi:

Substances chimiques

Cannabinoids 0
Medical Marijuana 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-259

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001082
Pays : United States

Auteurs

Nicole V Tolan (NV)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Matthew D Krasowski (MD)

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Patrick C Mathias (PC)

Department of Laboratory Medicine and Pathology, Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, WA, USA.

Joesph R Wiencek (JR)

Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.

Nikolina Babic (N)

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.

Peter R Chai (PR)

Harvard Medical School, Boston, MA, USA.
Department of Emergency Medicine, Division of Medical Toxicology, Brigham and Women's Hospital, Boston, MA, USA.
The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
The Fenway Institute, Boston, MA, USA.

Allison B Chambliss (AB)

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Ibrahim Choucair (I)

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.

Christiana A Demetriou (CA)

Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus, USA.

Timothy B Erickson (TB)

Harvard Medical School, Boston, MA, USA.
Department of Emergency Medicine, Division of Medical Toxicology, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Humanitarian Initiative, Cambridge, MA, USA.

Matthew Feldhammer (M)

Department of Pathology and Laboratory Medicine, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA.

Deborah French (D)

Department of Laboratory Medicine, University of San Francisco, San Francisco, CA, USA.

Bryan D Hayes (BD)

Harvard Medical School, Boston, MA, USA.
Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.

Phillip Kang (P)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Joe M El-Khoury (JM)

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.

Claire E Knezevic (CE)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Andrew Monte (A)

University of Colorado Anschutz, Aurora, CO, USA.

Robert D Nerenz (RD)

Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Anthony O Okorodudu (AO)

University of Texas Medical Branch, Galveston, TX, USA.

Stephen M Roper (SM)

Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Alec Saitman (A)

Providence Regional Laboratories, Portland, OR, USA.

Vamsi Thiriveedhi (V)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Sacha N Uljon (SN)

Harvard Medical School, Boston, MA, USA.
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

Alexis Vest (A)

University of Colorado Anschutz, Aurora, CO, USA.

Alison Woodworth (A)

Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA.

Min Yu (M)

Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, USA.

Stacy E F Melanson (SEF)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH